The present study tested the hypotheses that 1) ER␣ in the brain plays a key role in the estrogen-protective effects against ANG II-induced hypertension, and 2) that the subfornical organ (SFO) is a key site where ER␣ mediates these protective actions. In this study, a "floxed" ER␣ transgenic mouse line (ER␣ flox ) was used to create models in which ER␣ was knocked down in the brain or just in the SFO. Female mice with ER␣ ablated in the nervous system (Nestin-ER␣ Ϫ mice) showed greater increases in blood pressure (BP) in response to ANG II. Furthermore, females with ER␣ knockdown specifically in the SFO [SFO adenovirus-Cre (Ad-Cre) injected ER␣ flox mice] also showed an enhanced pressor response to ANG II. Immunohistochemical (IHC), RT-PCR, and Western blot analyses revealed a marked reduction in the expression of ER␣ in nervous tissues and, in particular, in the SFO. These changes were not present in peripheral tissues in Nestin-ER␣ Ϫ mice or Ad-Cre-injected ER␣ flox mice. mRNA expression of components of the renin-angiotensin system in the lamina terminalis were upregulated in Nestin-ER␣ Ϫ mice. Moreover, ganglionic blockade on day 7 after ANG II infusions resulted in a greater reduction of BP in Nestin-ER␣ Ϫ mice or SFO Ad-Cre-injected mice, suggesting that knockdown of ER␣ in the nervous system or the SFO alone augments central ANG II-induced increase in sympathetic tone. The results indicate that interfering with the action of estrogen on SFO ER␣ is sufficient to abolish the protective effects of estrogen against ANG II-induced hypertension.
THERE IS CONSIDERABLE EVIDENCE from studies in both humans and animal models that estrogen modulates cardiovascular physiology and pathophysiology (9, 26) . Previous studies from our laboratories have shown that central estrogen and estrogen receptor (ER) activation is critically involved in the protection against ANG II or aldosterone (Aldo)-dependent hypertension (34, 36, 37) . In these studies, central infusion of estrogen attenuated ANG II-or Aldo-induced hypertension in both males and ovariectomized (OVX) females. In contrast, central blockade of ERs by nonselective antagonists increased ANG II or Aldo pressor effects in intact females (34, 36, 37) . Because there are multiple cytosolic ER subtypes (e.g., ER␣ and ER␤), it is not clear which ER subtype is responsible for the antihypertensive effect of central estrogen and, importantly, the central site of estrogen action.
Both ER␣ and ER␤, the two classic ER subtypes, have been shown to be expressed in key regions of the brain involved in blood pressure (BP) regulation (30) . Immunohistochemical (IHC) and molecular biological studies provide evidence for region-specific expression of ER subtypes in these nuclei. For example, ER␣ appears to predominate in the nucleus of the solitary tract (NTS)-and lamina terminalis (LT)-related structures [i.e., the subfornical organ (SFO), median preoptic nucleus (MnPO), organum vasculosum of the lamina terminalis (OVLT)], while ER␤ is most prominent in the paraventricular nucleus (PVN) (30) . We and others have shown that estrogen activation of central ERs, probably ER␣, in female mice protects against baroreflex dysfunction and hypertension induced by ANG II (21, 37) . In contrast, ER␤, but not ER␣, in both the PVN and rostral ventral lateral medulla (RVLM) contributes to the protective effects of estrogen against Aldoinduced hypertension (39) . These studies suggest that specific ER subtypes mediate the regulatory effect of estrogen on BP in different brain nuclei.
ANG II is an important factor in many forms of both clinical and experimental hypertension. Recent studies indicate that circulating ANG II increases sympathetic nervous system activity and BP via actions on the SFO, one of the key circumventricular organs (CVOs) lacking a blood-brain barrier (10, 18, 19) . Genomic overexpression of superoxide dismutase, deletion of the different NADPH oxidase subunits, or blockade of endoplasmic reticulum stress in the SFO prevents hypertension caused by chronic ANG II infusion (16, 22, (41) (42) (43) . This region is rich in both ANG II type 1 receptors (AT 1 R) and ER␣, but not ER␤. Under basal conditions, colocalization of ER␣ and AT 1 R is evident in the SFO (15, 24) . Previous studies from our laboratory have shown that in the SFO, estrogen attenuates ANG II-induced increases in cellular reactive oxygen species, which is a key intracellular signal produced by ANG II activation (40) . Electrophysiological evidence also shows that chronic administration of estrogen not only attenuates the basal spontaneous discharge of SFO neurons, but also reduces the response of these neurons to systemic infusions of ANG II (3) . This is further supported by the observations that iontophoretic application of estrogen to SFO neurons and that the acute systemic administration of estrogen inhibits the discharge of these neurons (31) . Taken together, these results implicate estrogen interaction with ANG II in the SFO to antagonize the centrally mediated effects of ANG II on sympathetic activity and the control of BP.
In vivo studies employing systemic or intracerebroventricular administration of ER agonist or antagonist cannot specifically identify the site of the protective actions of estrogen against the hypertensive actions of blood-borne ANG II and unequivocally the type of ER that is critical at that site. Therefore, it remains to be fully established that ER␣ mediates estrogen by actions on the brain and, more specifically, the role of the SFO in this effect. In the present study, using a "floxed" ER␣ transgenic mouse line harboring a LoxP-flanked (exon 3) for the ER␣ (ER␣ flox ) (1), we created a nervous system ER␣ knockout (Nestin-ER␣ Ϫ ) mouse by breeding of Nestin-Cre mice with ER␣ flox mice, and a SFO ER␣ knockdown mouse by injection of adenovirus-Cre (Ad-Cre) into the SFO of the ER␣ flox mice. Then, we applied these mouse models to determine whether ER␣ in the nervous system, especially in the SFO, is sufficient to account for the protective effect of estrogen against hypertension induced by circulating ANG II.
METHODS

Animals
All experiments were performed in female mice. A "floxed" ER␣ transgenic mouse line harboring a LoxP-flanked (exon 3) for the ER␣ (ER␣ flox ) was obtained from the University of Missouri and was used to create an animal model in which it is possible to knock out or knock down ER␣ in a targeted body structure/region. When male Nestin-Cre mice, which express Cre recombinase specifically in neuronal and glial precursor cells (32) , are bred with female ER␣ flox mice, about one-fourth of the progeny carry both ER␣ flox and Cre recombinase, which produces a genotype of nervous tissue-specific ER␣ ablation. These animals are referred to as Nestin-ER␣ Ϫ mice in this article. About one-fourth of the offspring from such breeding bear ER␣ flox but lack Cre recombinase (Con-ER␣ flox , i.e., the maternal phenotype). These two genotypes were the main strains used in this study. The generation of mice with an ER␣ inactivation (ER␣ Ϫ ) has previously been described. Cre/LoxP recombination was detected in embryos as early as the head-fold stage. By embryonic day (E) 15.5, recombination occurred in virtually all cells of the nervous system (5). These mice have a deletion in exon 3 of the ER␣ gene, and they do not express any of the isoforms of the ER␣ protein (6) . Moreover, these mice have similar body weight and normal levels of estradiol, testosterone, luteinizing hormone, and follicle-stimulating hormone compared with control mice (20) .
Tail DNA was isolated, and mouse genotyping was performed in progeny by using the Easy-DNA Kit (Invitrogen), as described by Gieske et al. (7) . The primer combination of ER␣P2F (5=-gtg tca gaa aga gac aat-3=) plus ER␣P3 (5=-ggc att acc act tct cct ggg agt ct-3=) was used to determine the presence or absence of LoxP sequences (flox 575 bp or ER␣ wild-type (WT) 543 bp) (Fig. 1A ) in brain representative areas, including brain stem and forebrain structures along the LT (i.e., SFO, MnPO, OVLT), and peripheral organs, such as the kidney and liver. ER␣P1 (5=-ttg ccc gat aac aat aac at-3=) and ER␣P3 were also used to further confirm whether the exon 3 was removed in the same tissues (Fig. 1A) , that is, the removal of the sequence of DNA binding domain and hormonal binding domain (ER␣ Ϫ 359 bp or ER␣ WT 889 bp). To generate mice specifically lacking ER␣ in the SFO, a replication-deficient adenovirus encoding Cre-recombinase (Ad-Cre, 1 ϫ 10 10 plaque-forming units/ml, 100 nl) or a control empty vector (Ad-Con) was injected into the ventral hippocampal commissure and allowed to diffuse ventrally into the SFO of the ER␣ flox mice, using methods described previously (29) . All mice were bred in the colony at the University of Iowa using harem breeding. After weaning at 3 wk of age, mice were housed individually in standard polypropylene cages placed in a temperatureand humidity-controlled facility with a 12:12-h light-dark cycle (0600 AM to 0600 PM). The mice were maintained on pelleted chow and had ad libitum access to water throughout. The female mice were divided into four groups: 1) control ER␣ flox mice (n ϭ 6), 2) Nestin-ER␣ Ϫ mice (n ϭ 7), 3) SFO Ad-Con-injected ER␣ flox mice (n ϭ 7), and 4) SFO Ad-Cre-injected ER␣ flox mice (n ϭ 7). These groups of mice were treated with ANG II subcutaneously. In addition, four identical groups (groups 1 and 2; n ϭ 6 each; groups 3 and 4; n ϭ 10 each) without ANG II treatment had their brains, kidneys, and livers collected for analysis of mRNA expression of ER␣ and reninangiotensin system (RAS) components, including angiotensinogen (AGT), renin, AT 1R, and angiotensin-converting enzyme (ACE) in the brain stem, LT, kidney, and liver, and for analysis of protein expression of ER␣ in the SFO.
All experiments were conducted in accordance with the National Institutes of Health's Guide for the Care and Use of Laboratory Animals, and experimental protocols were approved by the University of Iowa Animal Care and Use Committee.
Surgical Procedures
Telemetry probe implantation. Implantable mouse BP transmitters (TA11PA-C10, Data Sciences International) were used to directly measure arterial pressure in individual animals. The mice were anesthetized with a ketamine-xylazine mixture (100 mg/kg and 10 mg/kg). The carotid artery of the mouse was accessed with a ventral midline incision. The left carotid artery was isolated with fine-tipped vessel dilation forceps. Two occlusion sutures were placed beneath the artery. The elevated artery was punctured with a catheter introducer, and the telemetry catheter was inserted into the vessel. The catheter tip was advanced into the thoracic aorta so that ϳ3 mm of the thin-walled tip section could reside in the aorta. The sutures were tied and secured with tissue adhesive. Through the same ventral incision, a subcutaneous tunnel was formed across the right pectoral area and was enlarged to form a pocket along the right flank. The body of the transmitter was slipped into the pocket and secured with tissue adhesive. The ventral incision was then closed with a suture.
Osmotic pump implantation. The mice were anesthetized by inhalation of isoflurane to allow the implantation of osmotic pumps. Osmotic pumps (model 1002; Alzet), containing ANG II (Sigma Chemical) at a concentration sufficient to allow an infusion rate of 800 ng·kg Ϫ1 ·min Ϫ1 , were implanted subcutaneously on the back. SFO injection of adenovirus encoding Cre-recombinase. Replication-deficient adenoviruses encoding Cre recombinase (Ad-Cre) or a control empty vector (Ad-Con) were generated by the University of Iowa Gene Transfer Vector Core. After baseline BP and HR recordings were made, the mice were anesthetized with ketamine-xylazine mixture, and an injector was introduced into the SFO (AP, Ϫ0.2 mm; ML, 0.0 mm; and DV, 3.1 mm) for injection of Ad-Cre or Ad-Con (100 nl).
Immunohistochemical and histological verification. Upon completion of the in vivo protocols, mice were anesthetized and perfused transcardially with PBS followed by 4% paraformaldehyde. The brains were removed, postfixed in 4% paraformaldehyde for 1 h, and then cryoprotected for 2 days in 30% sucrose at 4°C. Frozen 20-m coronal sections were cut with a cryostat. The tissue was washed with PBS and then blocked with 10% donkey serum (Jackson Laboratory) in PBS containing 0.2% Triton X-100 for 1 h. Sections were then incubated with a rabbit ER␣ antibody (Upstate; 1:400) and a mouse Cre-specific antibody (1:100; Covance) for 48 h at 4°C in the dark. After being thoroughly washed with PBS, sections were incubated with rhodamine-conjugated donkey anti-mouse antibody and Cy2-conjugated donkey anti-rabbit antibody to detect Cre (red) and ER␣ (green) expression, respectively. Fluorescence was then identified using a confocal microscope. The locations of the SFO injections were verified by visualization of expression of Cre (red). The animals with missed injections were excluded from analysis.
Western blot analysis of ER␣ protein expression in the SFO. Fourteen days after SFO injections of Ad-Cre or Ad-Con, mice were deeply anesthetized with isoflurane. The brains were removed and stored at Ϫ80°C until assay. Micropunches were made to collect the SFO. Total cellular protein was isolated from tissue punches of the SFO and was analyzed for protein expression of ER␣ by Western blot analysis. Briefly, protein samples were mixed with equal volumes of SDS-PAGE buffer, loaded onto the 10% SDS-PAGE gel for electrophoresis, and then transferred to a PVDF membrane (Bio-Rad Laboratories). The membrane was probed with rabbit antibody for anti-ER␣ (1:1,000; Upstate) or anti-␤-actin (1:2,500; Cell Signaling), respectively. This was followed by horseradish peroxidase-labeled anti-rabbit secondary antibody (Santa Cruz Biotechnology), and then treated with an enhanced chemiluminesence reagent. Band intensities were quantified with Imager (Bio-Rad) software and were normalized to ␤-actin.
Measurement of mRNA expression in brain, kidney, and liver. Total RNA was isolated from the brain stem, LT, kidney, or liver using the TRIzol method (Invitrogen), and treated with DNase I (Invitrogen). RNA integrity was checked by gel electrophoresis. Total RNA was reverse transcribed using random hexamers following the manufacturer's instructions (Applied Biosystems). Real-time PCR was conducted using 200 -300 ng of cDNA and 500 nM of each primer in a 20-l reaction with iQ SYBR Green Supermix (Bio-Rad). Amplification cycles were conducted at 95°C for 3 min, followed by 40 cycles of 95°C for 15 s and annealing/extension at 60°C for 30 s. Reactions were performed in duplicate and analyzed using a C1000 thermocycler system (Bio-Rad). Samples that did not yield homogenous melt curves were excluded. Changes in mRNA expression levels were normalized to GAPDH levels and were calculated using the ⌬⌬Ct method. Results are expressed as relative fold change, mean of fold change Ϯ SE. Primers were purchased from Integrated DNA Technologies, and the sequences of the primers are shown in Table 1 .
Experimental Protocol
Measurement of BP and HR. All mice were allowed 10 days of recovery from transmitter implantation surgery before any measurements were made. Thereafter, BP and HR were telemetrically recorded and stored with the Dataquest A.R.T. data acquisition system (Data Sciences International). To determine the effects of ANG II on BP and HR in female mice with ER␣ knocked out in the nervous system, the osmotic pumps with ANG II were implanted subcutaneously in Nestin-ER␣ Ϫ and control ER␣ flox mice after 5 days of baseline recording. To determine the effects of ANG II on BP and HR in female mice with ER␣ knockdown in the SFO, Ad-Cre or Ad-Con was injected into the SFO (100 nl) of ER␣ flox mice. Beginning 7 days later, the mice were infused subcutaneously with ANG II for 7 days.
Evaluation of BP responses to autonomic blockade. The autonomic contribution to increased BP was assessed by administering the ganglionic blocker hexamethonium (30 mg/kg ip). Ganglionic blockade was repeated twice, once during the baseline period and then after 7 days of ANG II infusion. On the day of the ganglionic blockade experiments, BP was recorded for 20 min both before and after hexamethonium injection. After hexamethonium injection, the largest decrease in BP occurred within 5 min. This nadir (2-3 min) was recorded as the maximum fall in BP.
Data Analysis
Mean arterial pressure (MAP) and HR were collected for five baseline days and then for seven consecutive days after ANG II pump implantation or 14 consecutive days after SFO adenovirus injection plus ANG II pump implantation. Difference scores for MAP and for HR were calculated for each animal on the basis of the mean of the 5-day baseline values subtracted from the mean of the 7 days of ANG II treatment. One-way ANOVAs for the experimental groups were then conducted on the means of calculated difference scores. After establishing a significant ANOVA, post hoc analyses were performed with Tukey multiple-comparison tests between pairs of mean change scores. The same statistical method was also used to analyze the differences in the mean of the 5-day baseline vs. the mean of 7 days of treatment in animals within the same group and the differences in mRNA or protein expression of the ER␣ and the RAS components in the brain stem, LT, kidney, liver, and the SFO in Nestin-ER␣ Ϫ mice or Ad-Cre-injected mice vs. control ER␣ flox mice or Ad-Con-injected ER␣ flox mice, respectively. All data are expressed as means Ϯ SE. Statistical significance was set at P Ͻ 0.05.
RESULTS
The mice exhibited circadian organization of MAP and HR both before and during infusion of ANG II. ANG II infusion elicited increases in daytime and nighttime BPs. Consequently, all data were expressed as values averaged from daytime and nighttime measurements.
Genotyping and ER␣ mRNA Expression in Nestin-ER␣
Ϫ and Con-ER␣ flox Mice Figure 1A , top, shows the presence of the Cre recombinase gene in the genomic DNA of the Nestin-ER␣ Ϫ mouse but not in the genomic DNA of the Con-ER␣ flox mouse. PCR using ER␣ P2F and P3 primers was employed to detect the presence of LoxP sequences (flox 575 bp and WT 543 bp; Fig. 1A,  middle) . In the Con-ER␣ flox mouse with the absence of Cre, the bands of both flox (575 bp) and ER␣ WT (543 bp) were present in all tissues. In contrast, in the Nestin-ER␣ Ϫ mouse with the presence of Cre, the flox (575 bp) band was almost completely removed, and the ER␣ WT (543 bp) remained in the brain stem and LT. However, the flox (575 bp) band was still present in the liver and kidney, even in the presence of Cre. Furthermore, PCR using ER␣ P1 and P3 primers confirmed that exon 3 was deleted in the presence of Cre recombinase (Fig. 1A, bottom) . ER␣ 359 bp, a smaller DNA band, which was expressed only in the brain stem and LT of Nestin-ER␣ Ϫ mouse, indicated the removal of the sequence of DNA binding domain and hormonal binding domain (exon 3), while the ER␣ WT (889 bp) without deleting exon 3 was expressed in peripheral tissues of Nestin-ER␣ Ϫ mouse and in all tissues of Con-ER␣ flox mouse. Figure 1B shows the levels of ER␣ and ER␤ mRNA expression by RT-PCR in Nestin-ER␣ Ϫ mice. Accordingly, the ER␣ expression was significantly knocked down by approximately one-half in the brain stem and LT (P Ͻ 0.05; Table 2 ). However, there were no changes in peripheral tissues, including the kidney and liver (P Ͼ 0.05). In contrast, ER␤ expression was upregulated in the brain stem, kidney, and liver (P Ͻ 0.05), but there was no change in the LT (P Ͼ 0.05).
The Effect of Nervous System-Specific ER␣ Knockout on the mRNA Expression of RAS Components in the LT
In LT tissue collected from Nestin-ER␣ Ϫ mice, nervous system-specific ER␣ knockout produced a significant increase in the mRNA expression of renin, AT 1 R, and ACE (P Ͻ 0.05) but had no effect on the mRNA expression of AGT (P Ͼ 0.05) when compared with Con-ER␣ flox mice (Fig. 1C , Table 3 ).
Effects of ANG II on MAP and HR in Control ER␣ flox and Nestin-ER␣ Ϫ Mice
Baseline values for BP and HR were comparable in these two groups (Con-ER␣ flox mice: 104.4 Ϯ 1.8 mmHg and 593.5 Ϯ 9.2 beats/min; Nestin-ER␣ Ϫ mice: 105.7 Ϯ 1.7 mmHg and 609.2 Ϯ 12 beats/min). Seven days of ANG II infusion resulted in a 22.6 Ϯ 2.7 mmHg (P Ͻ 0.05) increase in MAP in Nestin-ER␣ Ϫ mice vs an 11.4 Ϯ 1.8 mmHg increase in Con-ER␣ flox mice (Fig. 2, A and C) . In contrast, the increase in BP with ANG II did not result in a decrease in HR in any group of mice (Fig. 2B) .
Effects of ANG II on MAP and HR in SFO Ad-Con-or AdCre-Injected ER␣ flox Mice
Baseline values for BP and HR were comparable in Ad-Coninjected ER␣ flox mice (105.5 Ϯ 1.8 mmHg and 597.7 Ϯ 8.9 beats/min; P Ͼ 0.05) and Ad-Cre-injected ER␣ flox mice (103.7 Ϯ 2.3 mmHg and 591.3 Ϯ 15.4 beats/min). Neither Ad-Cre nor Ad-Con injections had any effect on the basal BP and HR. Females receiving a control empty vector injection into the SFO showed a significant increase in BP induced by systemic infusion of ANG II (⌬10.3 Ϯ 1.2 mmHg; P Ͻ 0.05), but SFO Ad-Cre injection enhanced this pressor effect of ANG II (⌬19.5 Ϯ 2.6 mmHg; P Ͻ 0.05 vs. Ad-Con injected mice, Fig. 3, A and C) . ANG II infusion did not change HR in either SFO Ad-Con-injected or Ad-Cre-injected ER␣ flox mice (Fig. 3B) 
Localization and the Effects of SFO Adenoviral Delivery of Cre on ER␣ Expression
The locus of viral delivery of Cre to knockdown ER␣ in the SFO was verified by IHC and Western blot analyses. Figure 4A is an IHC photomicrograph, which illustrates the site of delivery and the cells affected in the SFO.
IHC showed that highly robust Cre expression was present in the SFO accompanied with a marked reduction in the expression of ER␣ (Fig. 4B) Ad-Cre injection leaked into the brain ventricle, as evidenced by finding that there was no apparent expression of Cre in the OVLT or in the AP/NTS (Fig. 4C) and that there was robust ER␣ expression apparent in these regions. In the SFO of Ad-Con-injected mice, there was clear ER␣ expression, but no Cre expression (Fig. 4B) .
To confirm the effective knockdown of ER␣ in the SFO with these viruses, we performed a Western blot analysis on the . A: photomicrograph that illustrates the anatomical placement of the subfornical organ (SFO) cannula and the injection site. SFO Ad-Cre-injected ER␣ flox mice showed reduced ER␣ staining (green) in the SFO that paralleled intense Cre staining (red) in this site. The injections were targeted to the ventral hippocampal commissure so that injectate would diffuse into the SFO to minimize mechanical damage to the SFO proper (B). C: robust ER␣ expression was seen in the OVLT or AP/NTS, but Cre expression could not be detected in these sites, indicating that the injected Ad-Cre was not likely to have leaked into the brain ventricle. micropunches taken from the SFO. As shown in Fig. 5 , A and B, ER␣ protein level was significantly reduced in mice injected with Ad-Cre by ϳ70% when compared with mice injected with the control vector, Ad-Con. Figure 6 shows the decrease in BP produced by acute ganglionic blockade in all groups of female mice. The hexamethonium-induced decreases in BP were comparable in all groups before infusion of ANG II. Following 7 days of ANG II infusion, acute hexamethonium injection resulted in 57.0 Ϯ 6.3 and 48.8 Ϯ 5.2 mmHg decreases in BP in Nestin-ER␣ Ϫ mice (Fig. 6A) and SFO Ad-Cre-injected mice (Fig. 6B) , respectively. Both ER␣ knockdown groups showed significantly greater decreases in BP following hexamethonium relative to that seen in the Con-ER␣ flox mice (Ϫ44.3 Ϯ 3.4 mmHg; P Ͻ 0.05) and Ad-Con-injected mice (Ϫ39.0 Ϯ 6.5 mmHg; P Ͻ 0.05) given ANG II.
Effects of Autonomic Blockade on BP
DISCUSSION
The main findings of this study are that 1) the nervous system ER␣ is required for protective effects of estrogen against hypertension induced by systemic administration of ANG II, 2) the SFO is a key site where estrogen/ER␣ interacts with blood-borne ANG II, and 3) the augmented hypertensive effect of ANG II action on the nervous system by way of the SFO in ER␣ knockdown females involves increased sympathetic outflow.
We have previously reported that both removal of the ovaries and global knockout of ER␣ augment the pressor effects of ANG II in female mice. These data suggest that there is an important role for ER␣ in mediating the effects of estrogen in this mouse model with no significant compensation from other pathways (36, 37) . In intact WT females, central, but not peripheral, administration of the ER antagonist ICI182,780 augmented increases in BP by ANG II (37) . These results further indicate that it is central ERs that mediate estrogen's protective effects in this hypertension model. However, in these previous studies, we did not directly test the hypothesis that the inhibitory effects of estrogen on the ANG II-induced increase in BP can be unequivocally attributable to central ER␣, even though ICI182,780 is known to have a high affinity for the ER␣ (33) . In the present study, we used the Nestin-Cre mouse, which is a well-characterized model, combined with other interventions for deleting gene expression in the nervous system (32) , and a floxed ER␣ mouse line to create a mouse model to specifically delete ER␣ in the nervous system. The specificity of the mouse model was verified by using RT-PCR and Cre expression showing that there was impaired ER␣ mRNA expression in brain tissues but not in the kidney and liver. The deletion of ER␣ in the nervous system significantly augmented this pressor effect of ANG II to an extent similar to that observed in global ER␣ knockout mice or the mice treated with central nonselective ER antagonist during ANG II infusion. These findings confirm the results and hypothesis derived from our previous studies, indicating that central ER␣ mediates a protective effect of estrogen against ANG II-induced hypertension. The SFO lies outside the blood-brain barrier and has long been considered to be a critical peripheral-central interface for the cardiovascular actions of the circulating RAS (18) . This CVO not only has access to circulating and intraventricular ANG II, but also can generate ANG II from AGT de novo (25, 28) . Early microinjection, lesion, and autoradiographic studies provided physiological and anatomical evidence of the critical contribution of the SFO in mediating the central actions of ANG II. Importantly, the centrally mediated effects of systemically administered ANG II on BP and the secretion of vasopressin and oxytocin are all abolished by lesions of the SFO (18) . In recent studies, genomic deletion of AGT, NADPH oxidase subunits, and endoplasmic reticulum in the SFO alone prevented the pressor effects induced by systemic ANG II infusion, clearly highlighting the SFO as an essential central site for circulating ANG II effects (16, 22, 25, 28, (41) (42) (43) . Given that the SFO is rich in both AT 1 R and ER␣ and that they are colocalized in this structure (15, 24) , it is likely that the SFO is a site where estrogen can antagonize ANG II pressor effects via the interactions between ER␣ and AT 1 R. Viral delivery of Cre recombinase provides a valuable tool for the region-specific ablation of gene expression (12) . A series of studies from Davisson and colleagues (16, 22, 25, 28, (41) (42) (43) used the Cre-LoxP recombinase system to specifically dissect neural pathways, such as AGT, NADPH oxidase subunits, and others in the SFO. Using a similar strategy, we employed stereotaxic delivery of Ad-Cre into the SFO in ER␣ flox mice in the present study. Immunohistochemistry revealed significantly reduced ER␣ staining in the SFO along with intense Cre staining at this site in Ad-Cre-treated ER␣ flox mice. The knockdown of ER␣ protein expression in the SFO was confirmed by Western blot analysis. Functionally, the SFO-specific knockdown of ER␣ resulted in a significant augmentation of the pressor effect induced by ANG II. These results further substantiate the method that conditional ER␣ gene deletion can be achieved in the SFO by using the Cre recombinase/LoxP system in combination with viral gene transfer of Cre and that it is SFO ER␣ that mediates the protective effects of estrogen against the development of blood-borne ANG II-induced hypertension.
The chronic phase of ANG II-induced hypertension is associated with increased sympathetic nerve activity (14, 23) . We have previously shown that female mice are able to buffer the ANG II-induced increases in BP better than the males because they have reduced activation of the sympathetic nervous system (36) . Central ERs, probably ER␣, play a mediating role in buffering this ANG II-induced increase in sympathetic nervous system activity (37) . The present study confirms and extends these previous studies by showing that Nestin-ER␣ Ϫ mice or SFO Ad-Cre-injected mice showed greater increases in BP during ANG II infusion and greater falls in BP after ganglionic blockade compared with control animals. These results indicate that central ER␣ activation, especially SFO ER␣ activation, inhibits ANG II-induced increases in sympathetic outflow, thus contributing to the protective effects of estrogen against hypertension.
There is increasing evidence that the protective effects of estrogen can be attributed, at least in part, to modulating the expression of RAS components in the central nervous system (9, 26, 35) . Recent studies have shown that OVX increased ACE1 and AT 1 R activity, binding densities, and mRNA expression in the SFO and in the hypothalamus, including the PVN. These effects were prevented by restoration of normal estrogen levels (4, 13) . Our previous studies also showed that subpressor doses of ANG II mainly upregulated ACE1 and AT 1 R expression in the LT to cause increased sensitization in the absence of estrogen (38) . In the present study, we demonstrate further that ablation of nervous system ER␣ significantly upregulated mRNA expression of renin, ACE1, and AT 1 R in LT structures, which includes the SFO. This may indicate why females are more responsive to ANG II in the absence of SFO ER␣. Whereas, it should be noted that ER␣ knockdown in the nervous system not only modulates the mRNA expression of RAS components in the SFO, but also may affect the expression of RAS in downstream nuclei that are inside the bloodbrain barrier such as PVN and RVLM. It is possible that the changes in RAS components in the PVN and RVLM may also be involved in the enhanced BP response to ANG II in females lacking ER␣. Future studies will be necessary to determine the effect of ER␣ knockdown on the mRNA expression of RAS components in other brain regions.
The expression of ER␣ and ER␤ is region-specific in most brain nuclei implicated in the regulation of cardiovascular function (30) . We and others have demonstrated that it is ER␤, but not ER␣, in both the PVN and RVLM that mediate the attenuated effects of estrogen on resting BP, voltage-gated calcium currents, and the glutamate-induced or Aldo-induced increase in BP (8, 27, 39) . Therefore, it is possible that ER␤ in both the PVN and RVLM may be involved in estrogen's protection against ANG II-induced hypertension. However, previous studies indicate that the SFO is rich in only ER␣ and directly projects to the PVN and supraoptic nuclei (SON) (3, 15, 18, 31) . The increased BP induced by ANG II action at the SFO is mediated by both the release of vasopressin, as a result of activation of magnocellular neurosecretory neurons in the PVN and SON, and the activation of parvocellular neurons in the PVN that innervate sympathoexcitatory neurons in the RVLM and spinal cord (11, 17, 18) . Thus, it can be hypothesized that ER␣ activation in the SFO plays a primary role in the protective effects of estrogen as a result of estrogen interaction with circulating ANG II first in the SFO to decrease activity in the descending neural pathway, while the effects of ER␤ activation in the PVN and RVLM are important for actions of estrogen on components controlling sympathetic tone located inside the blood-brain barrier. Surprisingly, upregulated ER␤ expression in the brain stem and peripheral organs, such as liver and kidney, and probably also in the PVN (not examined) in the present study had no compensatory role in antagonizing ANG II-induced increase in BP under the condition of reduced ER␣ in the SFO or nervous system. Taken together, our previous and current studies involving ANG II-mediated increases in BP in 1) OVX WT mice, 2) global ER␣ knockout mice, 3) Nestin-ER␣ Ϫ mice, and 4) SFO Ad-Cre-injected ER␣ flox mice provide converging lines of evidence indicating that ER␣ in the SFO plays a pivotal role in mediating effects of estrogen on hypertension induced by circulating ANG II.
Both ER␣ and ER␤ have been shown to be expressed in key regions of the brain involved in BP regulation (30) , and there are no major differences in the levels of expression in these areas between the sexes (15). Our previous study showed that the central activation of ERs by intracerebroventricular infusion of estrogen in male mice inhibits ANG II-induced increases in sympathetic outflow and attenuates hypertension. In in vitro brain slices of the SFO taken from male mice, estrogen treatment inhibits ANG II-induced increases in reactive oxygen species (40) . These observations suggest that estrogen and/or ER activation in the central nervous system also play a protective role in antagonizing ANG II-induced hypertension in males (40) . Therefore, studying the effect of estrogen and ER␣ interactions in the SFO and the protection against hypertension in males are important studies for the future.
Perspectives and Significance
The present study verified that central ER␣, especially in the SFO, mediates the protective effect of estrogen in the development of ANG II-induced hypertension in female mice. It has been shown that estrogen replacement after menopause is associated with negative effects such as an increased risk of breast cancer in certain populations (2) , which are often attributed to its agonistic activity without receptor subtype (ER␣ vs. ER␤) or tissue specificity. In addition to selective ER agonists and antagonists, selective ER modulators (SERMs), which act on ERs in a tissue-specific fashion, are being currently investigated in several fields. The current findings will aid in developing SERMs with favorable properties and tissue specificity that target SFO ER␣ to prevent and treat hypertension in postmenopausal women as well as men.
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